645 results about "Polyarthritis Rheumatica" patented technology

The invention discloses a novel benzofuran component in eupatorium chinense and application of the benzofuran component in anti-inflammatory activity. The obtained compound is separated from an eupatorium chinense extract. The eupatorium chinense root extract is separated by using an extraction method, macroporous adsorption resin impurity removal, Sephadex LH-20 gel column chromatography, high performance liquid chromatography and other methods. According to the present invention, all the separated compounds and the analogues thereof have good inhibition activity on target cyclooxygenase-2 of inflammation-related diseases, and have good inhibition activity on COX-2 enzyme, and the molecular docking experiment results show that the compounds and the target proteins have good binding energy. Therefore, the compound can be used for preparing drugs for treating inflammatory related diseases, or anti-inflammatory and analgesic drugs, or tumor drugs by inhibiting COX-2 enzyme, such as drugs for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, Alzheimer's disease and the like, and related natural lead compounds are provided.

The invention belongs to the field of biological medicines, and particularly relates to application of loganic acid in preparation of a medicine for treating arthritis. Specifically, through experimental research of a collagen-induced arthritis mouse model, the loganin acid is found to be capable of remarkably relieving arthritis symptoms, relieving joint swelling, synovitis and cartilage injury in a dose-dependent manner, and reducing the levels of proinflammatory factors TNF-alpha and IL-6 in plasma. By further combining 16S rRNA sequencing analysis, the loganic acid can remarkably regulate the intestinal microbiota structure of arthritis mice, increase the abundance of Lactobacillus murinus in the intestinal tract and promote the generation of tryptophan metabolite indole-3-acetic acid, so that the effect of resisting rheumatoid arthritis is achieved through an intestinal flora dependent mechanism. Therefore, the invention provides a new application of loganin acid in preparation of a medicine for treating arthritis, and the compound has further research and application values as a potential small molecule medicine.

Provided herein are compositions and methods for the treatment of an autoimmune or inflammatory disease, such as rheumatoid arthritis. Said compositions comprise a TNFR1 inhibitor. Some embodiments comprise combination therapy featuring the TNFR1 inhibitor with at least one additional anti-inflammatory therapeutic agent.

The present disclosure provides methods of treating rheumatoid arthritis comprising administering a MNK inhibitor.

The invention belongs to the technical field of food and medicine, and relates to application of corn germ concentrated powder in improvement of osteoarthritis. The invention particularly relates to application of corn germ concentrated powder, namely corn antioxidant multienzyme, in preparation of medicines or health-care foods for treating rheumatoid arthritis and osteoporosis. In the corn germ concentrated powder, superoxide dismutase / (U / g) is greater than or equal to 8500, glutathione peroxidase / (U / g) is greater than or equal to 5000, and catalase / (U / g) is greater than or equal to 750. The corn germ concentrated powder can also be prepared by the following method: cleaning corn, germinating, adding water into the germinated corn, grinding and pulping, adding a settling agent into the corn steep liquor, standing, taking supernate, adding part of sodium ascorbate, performing temperature-controlled concentration, adding the rest sodium ascorbate and a stabilizer into the concentrated solution, and uniformly mixing to obtain the corn germ concentrated powder. And drying at controlled temperature, crushing, and mixing with a proper amount of silicon dioxide. The prepared corn germ concentrated powder has the effect of resisting rheumatoid arthritis.

Disclosed in the present invention are a targeted immunotolerance vaccine, a preparation method therefor, and use thereof. The present invention separately modifies a rheumatoid arthritis-related autoantigen peptide and CTLA4 Ig with DSPE-PEG (DP) to prepare a targeted formulation DP-antigen peptide and a targeted formulation DP-CTLA4, which are then mixed to obtain the vaccine. The vaccine described in the present invention, after intravenous injection, binds to albumin in vivo by means of DSPE, "hitchhiking" on albumin to target and enrich in inflammatory lesions, the spleen, the liver, and other tolerance-inducing sites, inhibiting T cell activation, and inducing anergy and apoptosis of rheumatoid arthritis autoantigen-specific T cells, thereby achieving immunotolerance treatment and prevention of rheumatoid arthritis.

The invention belongs to the technical field of biomedicine, and particularly relates to application of DHX58 as a diagnostic marker and a therapeutic target of rheumatoid arthritis. Experiments prove that the DXH58 level in rheumatoid arthritis involved parts such as serum and synovial tissues of rheumatoid arthritis patients is remarkably increased, DHX58 and rheumatoid arthritis are positively correlated, and the DHX58 gene or DHX58 protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of rheumatoid arthritis. Experiments prove that the targeted DHX58 can be used as an effective way for treating rheumatoid arthritis. The application has important meanings for researching the effect of DHX58 in rheumatoid arthritis, understanding the mechanism of RA disease and developing a new treatment strategy.

The present invention discloses the use of 3,4-dihydropsoralen in the preparation of a drug for preventing or treating rheumatoid arthritis. The present invention simulates RA by constructing TNF-a-induced SW982 cells. The results show that 3,4-dihydropsoralen (DP) can downregulate the mRNA expression of inflammatory factors, chemokines, and matrix degrading enzymes through the IL-17 signaling pathway, and affect the IL-17 signaling pathway and the NF-κB signaling pathway to jointly exert an anti-inflammatory effect, thereby effectively improving rheumatoid arthritis. This provides a theoretical basis for the application of 3,4-dihydropsoralen in the clinical treatment of rheumatoid arthritis and opens up new therapeutic drugs and approaches.

The invention relates to a probiotic composition for treating rheumatoid arthritis and application thereof, and relates to the technical field of probiotic compositions.The probiotic composition for treating rheumatoid arthritis is prepared from, by weight, 10-40 parts of lactobacillus johnsonii LBJ 456, 10-30 parts of lactobacillus helveticus HH-LPH17 and 10-30 parts of lactobacillus acidophilus HH-LA26. The bifidobacterium longum subsp. Longum HH-BL18, the bifidobacterium bifidum HH-BB27 and the bifidobacterium longum subsp. Infantis HH-BI27 are prepared from the following raw materials in parts by weight: 10 to 40 parts of bifidobacterium longum subsp. Probiotic strains with specific effects are screened out, the combination proportion of the probiotic strains is optimized, the probiotic composition for treating rheumatoid arthritis is prepared, and a novel safe and effective adjuvant therapy method is provided for treatment of RA.

The invention provides a traditional Chinese medicine composition for treating rheumatic arthritis, a preparation and application, and belongs to the field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following medicinal raw materials: 12-18 parts of sailong bone, 6-12 parts of radix aconiti lateralis preparata, 3-9 parts of radix aconiti preparata, 9-15 parts of cassia twig, 1-4 parts of asarum, 9-15 parts of radix clematidis, 20-40 parts of astragalus membranaceus, 3-9 parts of scorpio, 9-15 parts of earthworm, 9-15 parts of caulis sinomenii, 12-18 parts of bighead atractylodes rhizome, 12-18 parts of poria cocos, 9-15 parts of gentiana macrophylla, 12-18 parts of angelica sinensis, 20-40 parts of caulis spatholobi, 9-15 parts of rhizoma drynariae, 12-18 parts of radix paeoniae alba, 3-9 parts of honey-fried licorice root and 6-12 parts of rhizoma zingiberis. According to the traditional Chinese medicine composition for treating rheumatic arthritis, the medicine raw material composition of the traditional Chinese medicine composition for treating rheumatic arthritis is reasonably designed, four pathological links of cold, dampness, stasis and deficiency of rheumatic arthritis are covered through precise compatibility of monarch, minister, assistant and guide, and the traditional Chinese medicine composition has triple curative effects of anti-inflammatory analgesia, immunoregulation and bone protection.

The invention discloses Witzia ciliaris NCU-33 and application thereof, and belongs to the technical field of microbial medicines. The bacillus coagulans NCU-33 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number of the bacillus coagulans NCU-33 is CGMCC NO.31779. The strain is separated from a fresh excrement sample of healthy people; the strain is capable of ameliorating and / or preventing rheumatoid arthritis by anti-inflammatory and immunomodulatory effects.

The invention provides a nitric oxide fluorescent probe with aggregation-induced emission characteristics and a preparation method and application thereof. The structural formula of the nitric oxide fluorescent probe is shown in the specification. The nitric oxide fluorescent probe provided by the invention is high in detection sensitivity, high in response speed, excellent in NO selectivity and AIE characteristic, wide in application range, not only suitable for liquid-phase and gas-phase NO detection, but also capable of realizing high-efficiency real-time detection of NO in body fluid, cells and living body samples, and wide in application prospect. The method can be used for diagnosis of diseases such as inflammation (rheumatoid arthritis), tumor microenvironment and the like, high-throughput drug screening and environment monitoring.

A method for determining if an agent is suitable for treating a Rheumatoid Arthritis (RA) patient, the method comprising determining the profile of a first, second and / or third marker panel in a sample from the patient, wherein the agent is selected from an agent that downregulates TNF mediated signalling, an agent that downregulates IL-6 mediated signalling and a B cell targeted therapy.

The application discloses a use of total iridoid glycosides in radix morindae officinalis in preparation of a medicine for reducing side effects of methotrexate, and the total iridoid glycosides in radix morindae officinalis are effective traditional Chinese medicine components prepared by extraction and separation from radix morindae officinalis medicinal materials. The total iridoid glycosides in radix morindae officinalis and main component crystal larkspur glycoside are combined with methotrexate to treat rheumatoid arthritis rats, and the animal experiment proves that the combined administration can effectively treat inflammation of the rheumatoid arthritis rats, and can inhibit bone loss, especially can effectively reduce side effects caused by methotrexate, reduce damage caused by methotrexate to the organism, make the application more safe and effective, and provide a new treatment strategy for rheumatoid arthritis.

The present invention relates to the use of an ROR inverse agonist or a pharmaceutically acceptable salt thereof for the preparation of a medicament for modulating ROR in a patient and / or for controlling autoimmune diseases and antibody-mediated rejection in a patient. The ROR-mediated diseases or autoimmune diseases include HIV, cancer, celiac disease, type 1 diabetes, Graves' disease (Graves' disease), inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease (Crohn's disease), cardiovascular disease, inflammatory disease, nervous system disorders, multiple sclerosis, and the like. Acute respiratory distress syndrome and arteriosclerosis.

Provided is a bispecific antibody and use thereof, the bispecific antibody comprising: a first domain that specifically binds the interleukin-6 receptor IL-6R, and a second domain that specifically binds interleukin-23. The bispecific antibody can simultaneously target IL-6R and IL-23p19, with stronger specificity, more accurately targeting tumor cells and reducing the adverse effects of off-target toxicity and can perform a unique function to play a biological function that is difficult to achieve with monoclonal antibody drugs. Compared with monoclonal antibody combination therapies, it can also effectively reduce the cost of treatment and break the current upper limit of therapeutic efficacy in the treatment of autoimmune diseases such as rheumatoid arthritis and IBD.

The application relates to fused pyrimidinone derivatives of the general formula (I) which act as agonists of Triggering Receptor Expressed on Myeloid cells 2 (TREM2) useful for the treatment of Parkinson's disease, rheumatoid arthritis, Alzheimer's disease, amyotrophic lateral sclerosis, Nasu-Hakola disease, frontotemporal dementia, multiple sclerosis, prion disease, and stroke.

The present invention relates to a composition comprising 4-hexylresorcinol (4-HR) as an active ingredient for prevention or treatment of a bone disease, and a formulation thereof. The composition comprising 4-hexylresorcinol (4-HR) as an active ingredient, or an ointment thereof was found to improve bone thickness, density, and strength and control bone remodeling by promoting the differentiation of osteoblasts and suppressing the proliferation and differentiation of osteoclasts in osteoporosis-induced animal models. Thus, the composition or ointment comprising 4-hexylresorcinol (4-HR) as an active ingredient can be provided as a therapeutic agent for bone diseases including bone fracture, osteoarthritis, rheumatoid arthritis, and osteoporosis.

1. The name of this design product: Rehabilitation training equipment. 2. Purpose of this design product: used for the rehabilitation of rheumatoid arthritis. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the design points: Stereoscopic drawing 1.

The invention provides a preparation method and application of graphene pain-relieving health-care paste, and the method comprises the following steps: mixing carrageenan with water to obtain a carrageenan solution, and carrying out ionization degradation on the carrageenan solution to obtain a carrageenan oligosaccharide solution; the preparation method comprises the following steps: stirring graphene oxide and a carrageenan oligosaccharide solution, cleaning to obtain a mixed solution, adding sodium alginate into the mixed solution to prepare a gel precursor, and adding an anhydrous calcium chloride solution and effective components into the gel precursor to obtain the pain-relieving gel, and drying the gel to obtain the health-care paste. The health-care ointment has the effects of promoting blood circulation, activating collaterals and inhibiting inflammation, and is suitable for various chronic pains such as rheumatic arthritis and lumbar muscle degeneration and acute pains such as traumatic injury and muscle strain; the composition is also suitable for auxiliary relieving of postoperative pain, and has safety and long-term effect. Due to the thermal conductivity of the graphene oxide in the health-care cream, local skin blood circulation can be accelerated, the permeation efficiency of the herbal extract is improved, and the medicine effect of the effective components is improved.

The invention discloses a traditional Chinese medicine liniment for treating rheumatoid arthritis and a preparation process thereof, the traditional Chinese medicine liniment is composed of a wind-dispelling and pain-relieving liquid medicine and auxiliary materials, the wind-dispelling and pain-relieving liquid medicine contains eight traditional Chinese medicines of thorny elaeagnus root, erythrina bark, kadsura longepedunculata root, waxberry root, ardisia crenata, rose mallow root, glabrous sarcandra herb and wikstroemia canescens root, and is prepared by ultrasonic extraction; the auxiliary materials comprise polyvinyl alcohol, a chitosan-acetic acid solution, glycerol, azone, methylparaben, vanillyl butyl ether and ethanol. The liniment is short in film forming time and good in stability, has excellent transdermal absorption performance and antioxidant activity, can remarkably relieve joint swelling of RA model mice, improve the pain threshold value, improve joint pathological injuries, achieve local precise long-acting administration, reduce side effects of the whole body and improve patient compliance, is suitable for clinical treatment of RA, and has a wide application prospect. The problems that an existing rheumatoid arthritis treatment medicine is large in side effect, and a traditional Chinese medicine preparation is short in efficacy duration and inconvenient to use are solved.

The invention belongs to the technical field of biomedicine, and particularly relates to WTAP as a clinical diagnosis marker for rheumatoid arthritis and application of the WTAP. Experiments prove that the WTAP level in rheumatoid arthritis involved parts such as serum and synovial tissues of rheumatoid arthritis patients is remarkably higher than that of normal people, the WTAP and the rheumatoid arthritis are positively correlated, and the WTAP gene or WTAP protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of the rheumatoid arthritis; the CIA mouse with the WTAP gene knocked out shows that the illness state is relieved, and the symptoms are relieved, so that the WTAP can be used as an effective target for treating rheumatoid arthritis.

The present disclosure relates to an orthogonal system comprising a first bi-specific polypeptide that comprises D-streptavidin or a variant thereof covalently linked to an antibody or antibody fragment and a second bi-specific polypeptide that comprises L-biotin covalently linked to a therapeutic or diagnostic agent. The disclosed systems can be useful in, for example, treating a disease or a condition (e.g., cancer, non-Hodgkin lymphoma, multiple sclerosis, Crohn's disease, rheumatoid arthritis, asthma, macular degeneration, psoriasis, Hodgkin lymphoma, paroxysmal nocturnal hemoglobinuria, X-linked hypophosphatemia). Also described are peptides and polypeptides useful in preparing the disclosed bi-specific polypeptides and methods of making same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The invention discloses nux vomica for intervening in rheumatoid arthritis and a processing method and application thereof, and belongs to the technical field of traditional Chinese medicinal material processing. The processing method comprises the following steps: decocting crude semen strychni with a water decoction of rhizoma atractylodis macrocephalae, filtering, and drying filter residues to obtain the processed semen strychni. According to the processing method, the medicine effect and safety of the semen strychni are remarkably improved through the unique processing technology that the rhizoma atractylodis macrocephalae water decoction is adopted to decoct the semen strychni crude product, the original anti-inflammatory, analgesic and immunoregulation activity of the rhizoma atractylodis macrocephalae and the semen strychni crude product are reserved, the synergistic interaction effect is generated, the toxicity of the semen strychni is systematically reduced, and the effect is remarkable. The pharmaceutical safety is greatly improved while the treatment effect is enhanced, and the pharmaceutical composition has important clinical application value and market prospect.

The invention discloses a traditional Chinese medicine composition for treating arthralgia, a traditional Chinese medicine preparation and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine, and the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 10-20 parts of vine of multiflower knotweed, 5-14 parts of rhizoma anemarrhenae, 10-20 parts of dandelion and 10-20 parts of bunge corydalis herb. The composition has a good treatment effect on rheumatoid arthritis, arthritis, arthralgia, muscular pain and the like caused by damp-heat, and can effectively solve the problem of limitation of existing medicines.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of oleanolic acid in promoting chondrogenic differentiation of chondrocytes. This invention discovers that oleanolic acid promotes the expression of proteoglycans and calcium deposition in ATDC5 cells undergoing chondrogenic differentiation, and also promotes the expression of ATDC5 cell chondrogenic differentiation markers. Therefore, it has the potential to be formulated into a drug that can promote chondrogenic differentiation of chondrocytes, thereby promoting cartilage repair and regeneration for the treatment of osteoarthritis and rheumatoid arthritis.

The present disclosure relates to compounds of Formula I and pharmaceutically acceptable salts thereof, wherein X, R1-R4, n and m have the meanings given in the specification. The compounds of formula I exhibit GPR183 antagonistic activity and are therefore useful in the treatment or prevention of disorders, conditions or diseases to which GRP183 antagonists are applicable, such as chronic pain, such as osteoarthritis, chronic lumbago, neuropathic pain, and immune system diseases, such as inflammatory bowel diseases, such as colitis and Crohn's disease, multiple sclerosis, rheumatoid arthritis, inflammatory lung diseases, and the like. , such as asthma and psoriasis.

The present invention relates to a composition and method for treating rheumatoid arthritis, comprising interleukins (ILs), including IL-1β, stimulated human umbilical cord mesenchymal stem cells (hUCMSCs). The IL stimulated hUCMSCs of the present invention may induce the apoptosis of fibroblast-like synoviocytes rheumatoid arthritis (HFLS-RA) cells. IL stimulated hUCMSCs are useful to alleviate RA symptoms, such as inflammation, swelling and cartilage erosion, and exhibit therapeutic effects on rheumatoid arthritis.

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and / or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and / or prophylaxis of diseases, especially for treatment and / or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.